Dupixent late-breaking phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis in children 1 to 11 years old

Press/Media

Period	12 Oct 2022

Media coverage

Title	Dupixent late-breaking phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis in children 1 to 11 years old
Media name/outlet	PharmaBiz
Country/Territory	India
Date	12/10/22
URL	www.pharmabiz.com/NewsDetails.aspx?aid=153757&sid=2
Persons	Mirna Chehade